Dr. Mridul Agrawal studied human medicine and health economics (M.Sc.) at the University of Heidelberg and received his doctorate there in 2015. As part of his studies, he spent time abroad at the Johns Hopkins University School of Medicine in Baltimore and the University of Zurich. Dr. Agrawal began his medical and scientific career at the Ulm University Hospital in the field of hematology / oncology (cancer medicine). Since 2018 he has been working as a scientist at the Dana-Farber Cancer Institute at Harvard Medical School in Boston (USA). Dr. Agrawal is also the founder of iuvando Health, a digital health startup in the field of precision oncology, which individually informs cancer patients about new therapy methods within the framework of clinical studies. iuvando Health was recognized as the winner of the EY Public Value Award in 2019 and received the EIT Health Headstart Award in 2020, which is sponsored by the European Union.